Inactive

Amendment 0001 - Q&A posted and response deadline extended to 8/25/2022 at 9 am ET The National Institute of Neurological Disorders and Stroke (NINDS) has a need for biological therapeutics assay deve... Amendment 0001 - Q&A posted and response deadline extended to 8/25/2022 at 9 am ET The National Institute of Neurological Disorders and Stroke (NINDS) has a need for biological therapeutics assay development subject matter expert (SME) consulting services. SME consultants will be required to provide technical recommendations and advice that will support the translational development of novel therapeutics (Biologics) for NIH drug discovery and development programs. The support included in the resultant contract(s) will cover bioassay development and/or qualification/validation for a variety of biologics, including but not limited to: monoclonal antibodies, peptide therapeutics, viral vector therapeutics (e.g., AAV, lentiviruses, etc.), nucleic acid and cell-based therapeutics, proteins, or other biological therapeutic modalities. Preferably, consultants should have significant expertise supporting assay development for more than one biological therapeutic modality (e.g., monoclonals, peptides, ASOs and viral vectors).